Press Releases

Date Title and Summary Additional Formats
Toggle Summary Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) in Combination with Chemotherapy for Adults with Previously Untreated Systemic Anaplastic Large Cell Lymphoma or Other CD30-Expressing Peripheral T-Cell Lymphomas
-First FDA-Approved Regimen in Frontline Peripheral T-Cell Lymphoma- -FDA Approval Based on Results from the Phase 3 ECHELON-2 Clinical Trial; Data to be Presented at the 2018 ASH Annual Meeting- -Application Approved Less Than Two Weeks After Submission Under FDA Real-Time Oncology Review Pilot
View HTML
Toggle Summary FDA Grants Breakthrough Therapy Designation to ADCETRIS® (Brentuximab Vedotin) for Frontline Peripheral T-Cell Lymphomas
-Designation Based on Positive Phase 3 ECHELON-2 Trial Evaluating ADCETRIS in Frontline CD30-Expressing Peripheral T-Cell Lymphomas; Data to be Presented at Upcoming American Society of Hematology Annual Meeting in December- BOTHELL, Wash. --(BUSINESS WIRE)--Nov. 15, 2018-- Seattle Genetics, Inc.
View HTML
Toggle Summary Seattle Genetics Initiates Phase 1 Clinical Trial of SEA-BCMA for Patients with Relapsed or Refractory Multiple Myeloma
-SEA-BCMA is a Novel Empowered Antibody Targeting BCMA for Multiple Myeloma- -Adds to Seattle Genetics’ Robust Clinical-Stage Development Pipeline across Multiple Hematologic and Solid Tumors- BOTHELL, Wash. --(BUSINESS WIRE)--Nov. 14, 2018-- Seattle Genetics, Inc.
View HTML
Toggle Summary Seattle Genetics to Present at the Credit Suisse 27th Annual Healthcare Conference
BOTHELL, Wash. --(BUSINESS WIRE)--Nov. 6, 2018-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Credit Suisse 27 th Annual Healthcare Conference on Tuesday, November 13, 2018 at 2:15 p.m. Mountain Time . The presentation will be webcast live and available
View HTML
Toggle Summary Seattle Genetics Submits Supplemental Biologics License Application for ADCETRIS® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas
-Submission Based on Positive Phase 3 ECHELON-2 Trial Evaluating ADCETRIS in Frontline CD30-Expressing Peripheral T-Cell Lymphoma- -ECHELON-2 Data will be Presented at Upcoming American Society of Hematology Annual Meeting in December- BOTHELL, Wash. --(BUSINESS WIRE)--Nov.
View HTML
Toggle Summary Seattle Genetics Announces More Than 30 Presentations at ASH 2018 Highlighting Progress with Broad ADCETRIS® (Brentuximab Vedotin) Development Program
-Positive Phase 3 ECHELON-2 Clinical Trial Results to be Presented in Oral Session on Monday, December 3 rd - BOTHELL, Wash. --(BUSINESS WIRE)--Nov. 1, 2018-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that 31 abstracts featuring data from the broad ADCETRIS (brentuximab vedotin)
View HTML
Toggle Summary Seattle Genetics Announces Multiple Data Presentations Evaluating ADCETRIS® (Brentuximab Vedotin) in Patients with Hodgkin Lymphoma at ISHL 2018
-Encore and Additional Analyses from Phase 3 ECHELON-1 Trial Evaluating ADCETRIS in Combination with Chemotherapy in Frontline Advanced HL- -Interim Results from Ongoing Studies of ADCETRIS plus Opdivo ® (Nivolumab) in Frontline or Relapsed Hodgkin Lymphoma- -Five-Year Results from Phase 3 AETHERA
View HTML
Toggle Summary Seattle Genetics Reports Third Quarter 2018 Financial Results
-ADCETRIS ® (Brentuximab Vedotin) Net Sales in U.S. and Canada of $127.0 Million in the Third Quarter- -Positive Top-line Data from ADCETRIS Phase 3 ECHELON-2 Trial in Frontline PTCL; Supplemental BLA Planned for November 2018 ; Full Data to be Presented at ASH Annual Meeting- -Top-line Data from
View HTML
Toggle Summary Genmab and Seattle Genetics Announce Tisotumab Vedotin Data to Be Presented at ESMO 2018 Congress
Data presented from updated analysis of full innovaTV 201 expansion cohort in recurrent or metastatic cervical cancer COPENHAGEN, Denmark & BOTHELL, Wash. --(BUSINESS WIRE)--Oct. 8, 2018-- Genmab A/S (Nasdaq Copenhagen: GEN) and Seattle Genetics, Inc.
View HTML
Toggle Summary Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter Financial Results on October 25, 2018
BOTHELL, Wash. --(BUSINESS WIRE)--Oct. 3, 2018-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its third quarter financial results on Thursday, October 25, 2018 after the close of financial markets. Following the announcement, company management will host a conference
View HTML